Tenaya Therapeutics Inc (TNYA)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$0.39+0.26%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Tenaya Therapeutics Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	2.54M
EPS	—	-0.098
Annual ending 2026-12-31
Revenue	—	3.99M
EPS	—	-0.48
Annual ending 2027-12-31
Revenue	—	2M
EPS	—	-0.366

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Progress in gene therapy trials and pipeline development	A primary condition in Tenaya Therapeutics Inc's published investment case. The stated target is Positive interim trial data and advancement of 15 gene targets by mid-2027.	Improving	failure to advance key gene therapy trials or pipeline targets by mid-2027	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Maintain funding to support operations through mid-2027	The company plans to fund operations through mid-2027 using collaboration payments.	Intact	cash runway falls short of mid-2027 funding needs	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Resolve Nasdaq minimum bid price compliance	A supporting condition in Tenaya Therapeutics Inc's published investment case. The stated target is Compliance with Nasdaq minimum bid price rules by end of 2026.	Under Pressure	failure to regain Nasdaq compliance by end of 2026	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPSUnavailable

$-0.41 → Unavailable · observed estimates

FY2027 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-0.41	Unavailable	5 / 4
2026-07-25	$-0.41	Unavailable	5 / 4
2026-07-26	$-0.41	Unavailable	5 / 4
2026-07-27	$-0.41	Unavailable	5 / 4
2026-07-28	$-0.41	Unavailable	5 / 4
2026-07-29	$-0.41	Unavailable	5 / 4
2026-07-30	$-0.41	Unavailable	5 / 4
2026-07-31	Unavailable	Unavailable	4 / 2
2026-08-01	Unavailable	Unavailable	4 / 2
2026-08-02	$-0.41	Unavailable	5 / 4
2026-08-03	$-0.41	Unavailable	5 / 4
2026-08-04	Unavailable	Unavailable	4 / 2
2026-08-05	Unavailable	Unavailable	4 / 2
2026-08-06	Unavailable	Unavailable	4 / 2
2026-08-08	$-0.43	Unavailable	5 / 3
2026-08-09	$-0.43	Unavailable	5 / 3
2026-08-10	Unavailable	Unavailable	4 / 2
2026-08-12	Unavailable	Unavailable	4 / 2
2026-08-13	Unavailable	Unavailable	4 / 2
2026-08-14	Unavailable	Unavailable	4 / 2
2026-08-15	Unavailable	Unavailable	4 / 2
2026-08-16	Unavailable	Unavailable	3 / 2
2026-08-17	Unavailable	Unavailable	3 / 2
2026-08-18	Unavailable	Unavailable	4 / 3
2026-08-19	Unavailable	Unavailable	4 / 3
2026-08-20	Unavailable	Unavailable	4 / 3
2026-08-21	Unavailable	Unavailable	4 / 3
2026-08-22	Unavailable	Unavailable	4 / 3
2026-08-23	Unavailable	Unavailable	4 / 3
2026-08-24	Unavailable	Unavailable	4 / 3
2026-08-25	Unavailable	Unavailable	4 / 3
2026-08-26	Unavailable	Unavailable	4 / 3
2026-08-27	Unavailable	Unavailable	4 / 3
2026-08-28	Unavailable	Unavailable	4 / 3
2026-08-29	Unavailable	Unavailable	4 / 3
2026-08-30	Unavailable	Unavailable	4 / 3
2026-08-31	Unavailable	Unavailable	4 / 3
2026-09-01	Unavailable	Unavailable	4 / 3
2026-09-02	Unavailable	Unavailable	4 / 3
2026-09-03	Unavailable	Unavailable	4 / 3
2026-09-04	Unavailable	Unavailable	4 / 3
2026-09-05	Unavailable	Unavailable	4 / 3
2026-09-06	Unavailable	Unavailable	4 / 3
2026-09-07	Unavailable	Unavailable	4 / 3
2026-09-08	Unavailable	Unavailable	4 / 3
2026-09-09	Unavailable	Unavailable	4 / 3
2026-09-10	Unavailable	Unavailable	4 / 3
2026-09-11	Unavailable	Unavailable	4 / 3
2026-09-12	Unavailable	Unavailable	4 / 3
2026-09-13	Unavailable	Unavailable	4 / 3
2026-09-14	Unavailable	Unavailable	4 / 3
2026-09-15	Unavailable	Unavailable	4 / 3
2026-09-16	Unavailable	Unavailable	4 / 3
2026-09-17	Unavailable	Unavailable	4 / 3
2026-09-18	Unavailable	Unavailable	4 / 3
2026-09-19	Unavailable	Unavailable	4 / 3
2026-09-20	Unavailable	Unavailable	4 / 3
2026-09-21	Unavailable	Unavailable	4 / 3
2026-09-22	Unavailable	Unavailable	4 / 3
2026-09-23	Unavailable	Unavailable	4 / 3
2026-09-24	Unavailable	Unavailable	4 / 3
2026-09-25	Unavailable	Unavailable	4 / 3
2026-09-26	Unavailable	Unavailable	4 / 3
2026-09-27	Unavailable	Unavailable	4 / 3
2026-09-28	Unavailable	Unavailable	4 / 3
2026-09-29	Unavailable	Unavailable	4 / 3
2026-09-30	Unavailable	Unavailable	4 / 3
2026-10-01	Unavailable	Unavailable	4 / 3
2026-10-02	Unavailable	Unavailable	4 / 3
2026-10-03	Unavailable	Unavailable	4 / 3
2026-10-04	Unavailable	Unavailable	4 / 3
2026-10-05	Unavailable	Unavailable	4 / 3
2026-10-06	Unavailable	Unavailable	4 / 3
2026-10-07	Unavailable	Unavailable	4 / 3
2026-10-08	Unavailable	Unavailable	4 / 3
2026-10-09	Unavailable	Unavailable	4 / 3
2026-10-10	Unavailable	Unavailable	4 / 3
2026-10-11	Unavailable	Unavailable	4 / 3
2026-10-12	Unavailable	Unavailable	4 / 3
2026-10-13	Unavailable	Unavailable	4 / 3
2026-10-14	Unavailable	Unavailable	4 / 3
2026-10-15	Unavailable	Unavailable	4 / 3
2026-10-16	Unavailable	Unavailable	4 / 3
2026-10-17	Unavailable	Unavailable	4 / 3
2026-10-18	Unavailable	Unavailable	4 / 3
2026-10-19	Unavailable	Unavailable	4 / 3
2026-10-20	Unavailable	Unavailable	4 / 3
2026-10-21	Unavailable	Unavailable	4 / 3
2026-10-22	Unavailable	Unavailable	4 / 3
2026-10-23	Unavailable	Unavailable	4 / 3
2026-10-24	Unavailable	Unavailable	4 / 3

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	8	0	0
2026-06-01	8	0	0
2026-07-01	8	0	0
2026-08-01	7	0	0
2026-09-01	7	0	0
2026-10-01	6	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 6 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Progress in gene therapy trials and pipeline developmentDirect metric needs a verified mapping
Maintain funding to support operations through mid-2027Direct metric needs a verified mapping
Resolve Nasdaq minimum bid price compliancePublished status: Under Pressure

Next proof point

Nov 9, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.0%Typical daily move · historical

Downside history

-77.5%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Tenaya Therapeutics Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is speculative clinical-stage growth, not an established earnings compounder. The multi-year thesis is in a watch state: key clinical and regulatory work is progressing, but recent financial performance is weak and confidence in the assessment is low.

What's priced into Tenaya Therapeutics Inc

The valuation model indicates TNYA is expensive versus peers, with much of the difference tied to potential future program value rather than current earnings. The expectations gap is marked, but model confidence is low, so the valuation signal is uncertain; the evidence does not point to broad market fragility beyond the valuation premium.

What the fundamentals likely do

Near term, losses and weak financial performance are likely to remain central because the evidence shows no established earnings base. Management is on track with TN-201 and TN-401 development and regulatory engagement, while TN-301 remains at an earlier stage. Cash was $78.1 million in 2026-Q2, and management expects funding through Q3 2027; a guidance cut or continued execution delays would add risk.

What Tenaya Therapeutics Inc hinges on

Over the next one to three years, the thesis hinges on safety and efficacy evidence for TN-201 and TN-401, progress toward pivotal trial plans, and whether TN-301 reaches planned clinical evaluation. Cash discipline and the stated runway also matter, while weaker employment data could pressure healthcare names and strong results from sector bellwethers could support sector momentum.